Amphetamine is more effective than methamphetamine at raising dopamine levels in the prefrontal cortex. The current study tested the hypothesis that norepinephrine transporters are involved in this difference. Using microdialysis, dopamine, norepinephrine, and serotonin were measured in the rat prefrontal cortex after administration of methamphetamine or amphetamine, with and without perfusion of desipramine. Amphetamine raised norepinephrine levels more than methamphetamine did. Desipramine raised dopamine and serotonin levels but did not alter metabolite levels. Desipramine attenuated the increase in dopamine by amphetamine while increasing the dopamine released by methamphetamine. These data suggest that methamphetamine and amphetamine differ in altering prefrontal cortical dopamine levels and in interacting with norepinephrine transporters. It is proposed that amphetamine releases dopamine in the prefrontal cortex primarily through norepinephrine transporters, whereas methamphetamine interacts minimally with norepinephrine transporters.
INTRODUCTION
Methamphetamine (METH) and amphetamine (AMPH) are both abused psychostimulants (1) . Previously, we have shown that 2 mg/kg AMPH was more effective than 2 mg/kg METH at raising extracellular dopamine (DA) levels in the prefrontal cortex (PFC), even though the two drugs had similar effects in the nucleus accumbens (NAC) (2) . However, DA uptake blockers, which increase DA in the NAC, have been shown to have no effect in the PFC (3) . This may be because the PFC has sparse DA innervation, with a low density of DA transporters (DAT), and few DAT per DA terminal (4) . The PFC does, however, have a large norepinephrine (NE) innervation compared to its DA innervation (5) , and NE transporters (NET) have a higher affinity for DA than NE (6) . This has led to the speculation that NET may largely be responsible for DA clearance in the PFC (7) . Indeed, NET blockers have been shown to increase PFC DA levels (7, 8) . The NAC, which has less NE innervation and a higher level of DAT, removes DA primarily by DAT with little or no contribution from NET (9) .
One experiment found that in the hippocampus, AMPH was more effective than METH at raising NE levels, suggesting that AMPH may be more effective than METH at blocking NET (10) . Therefore, it may be expected that in the PFC, where NET may contribute to the clearance of DA, AMPH's greater effectiveness than METH at raising DA levels may be due to AMPH's greater effectiveness at blocking DA removal through NET. If this were the case, then AMPH would also be more effective than METH at raising NE levels in the PFC. This would also explain why METH and AMPH could differ in raising DA levels in the PFC but have similar effects in the NAC, where NET has little effect on DA levels.
In order to test this hypothesis, the effects of METH and AMPH on NE levels in the PFC were measured using in vivo microdialysis on awake and freely moving Sprague-Dawley rats. To determine if blocking NET would eliminate the difference between the effects of METH and AMPH on DA in the PFC, DA and the DA metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were measured after METH or AMPH administration during reverse dialysis of the NET blocker desipramine. Serotonin (5-HT) levels were also measured. This experiment aimed not only to elucidate the mechanisms by which AMPH and METH release DA in the PFC but also to clarify the dynamics of DA clearance in the PFC; and this is the first study to measure DA metabolite levels during desipramine administration. If desipramine increases PFC DA mainly by blocking DA uptake by NET, then a decrease in DOPAC levels should result from the decrease in intracellular DA. Furthermore, this is also the first study to measure the effects of local desipramine on 5-HT levels in the PFC. The results of this study may have important implications for the treatment of METH and AMPH addiction and further clarify the complex regulation of DA, NE, and 5-HT levels in the PFC.
EXPERIMENTAL PROCEDURE
Animals. Naïve adult female Sprague-Dawley rats (Taconic, Germantown, NY, USA) weighing 250-275 g at the start of the experiments were used. Animals were group-housed in clear polyurethane cages in a colony room controlled for temperature and humidity on a 12-h light-dark schedule (lights on at 0700 h SO 4 , equivalent weight 184.5) were administered at 2 mg/kg, i.p., in 1 ml/kg saline. Doses refer to the weight of the salt, which result in METH and AMPH being administered at nearly identical equimolar doses of the free bases (10.8 mol/mg). Saline was administered i.p. in equal volume as a control.
Desipramine (Sigma Chemical Co.) was dissolved in the artificial cerebrospinal fluid (aCSF) perfusate at a concentration of 1 M and administered by reverse dialysis. Normal aCSF solution without desipramine was used as the control.
Surgery for Microdialysis. Animals were anesthetized with 50 mg/kg i.p. pentobarbital. A guide cannula (CMA, Acton, MA, USA) was stereotaxically implanted, such that, when inserted, the tip of the microdialysis probe would be located in the PFC at ϩ3.2 mm AP, 0.1 mm ML, and Ϫ6.1 mm DV (11) . Animals were given at least 4 days of recovery from surgery and housed individually during this time to prevent disturbances to the guide cannula.
Microdialysis Procedure. Animals were anesthetized with Brevital (38 mg/kg, i.p.) and a 2-mm microdialysis probe (O.D. 0.5 mm, shaft length 20 mm, cutoff 20,000 daltons; CMA) was inserted through the guide cannula. Animals were perfused with normal aCSF (146 mM NaCl, 1.2 mM CaCl 2 , 2.7 mM KCl, 1.0 mM MgCl 2 , filtered and degassed) at a flow rate of 1 l/min.
The next day, 20-min samples were collected from awake and freely moving animals during the light cycle into plastic microcentrifuge vials. To prevent the oxidation of catecholamines, 2 l of a 0.95 N perchloric acid solution containing 1.4 mM EDTA and 2.8 mM sodium metabisulfite were added to the vials. Baseline samples were collected for 2 h. For animals receiving desipramine treatment, a liquid switch (CMA) was used to switch the perfusates from normal aCSF to aCSF containing 1 M desipramine after the baseline samples; samples were collected for an additional 80 min.
Animals were then injected i.p. with either 2 mg/kg METH, 2 mg/kg AMPH, or 1 ml/kg saline. Samples were collected for an additional 3 h. At the end of the experiment, animals were anesthetized with Brevital (50 mg/kg, i.p.), probes were removed, and animals were sacrificed by decapitation. Brains were quickly removed and frozen for histological analysis.
HPLC Analysis of DA, 5-HT, DOPAC, and HVA. The HPLC system consisted of an ESA 580 pump (ESA Inc., Chelmsford, MA, USA) delivering mobile phase purchased from ESA (0.075 M sodium dihydrogenphosphate, monohydrate, 0.0017 M 1-octanesulfonic acid, 25 M EDTA in 10% HPLC grade acetonitrile, adjusted to a pH of 3 with phosphoric acid) at a flow rate of 0.53 ml/min. An ESA 540 autosampler injected 10 l of sample onto an ESA small-bore reversephase C-18 column (150 ϫ 3, partical size 3 m). Samples were detected by an ESA Coulochem II electrochemical detector, and the ESA microdialysis cell was set to a potential of ϩ250 mV. Chromatograms were recorded and analyzed using Hewlett-Packard Chemstation software.
HPLC Analysis of NA. Samples were analyzed for NE in a similar manner, with some exceptions. The mobile phase contained 75 mM lithium acetate, 4 mM 1-heptane sulfonic acid, 100 M EDTA, 8% HPLC grade methanol, brought to a pH of 4.7 with acetic acid, delivered at a flow rate of 60 l/min. A CMA 200 refrigerated microsampler injected 5 l onto an ESA microbore reverse phase C-18 column (150 ϫ 1, particle size 3 m) and an ESA amperometric analytical cell set to ϩ300 mV was used. Chromatograms were recorded and analyzed using ESA 501 Chromatograph Data System software.
Histology. Brains were sliced at 30-m coronal sections using a cryostat. The location of the microdialysis probe was carefully referenced to the atlas of Paxinos and Watson (11) , and animals with probes outside the ventromedial portion of the PFC were removed from analysis.
Data Analysis. Data were transformed to percent baseline, uncorrected for probe recovery. The effect of a single treatment was analyzed with an ANOVA with repeated measures on time. Post hoc tests were used to compare individual time points to baseline when appropriate. Significance was achieved when a time point was significantly different (P Ͻ 0.05) from all six baseline samples. Two or more groups were compared with a two-way ANOVA (time ϫ group). Post hoc tests were used to compare the same time point between groups when appropriate, significance being achieved when P Ͻ 0.05. Statistica software was used for all statistical calculations.
RESULTS

Basal Levels
The basal levels (mean Ϯ SEM) were 0.95 Ϯ 0.08 pg/ 6 l NA, 0.69 Ϯ 0.06 pg/10 l DA, 0.23 Ϯ 0.03 pg/10 l 5-HT, 82.16 Ϯ 8.26 pg/10 l DOPAC, and 153.73 Ϯ 8.67 pg/10 l HVA. Figure 1 shows the effect of METH and AMPH on NE release in the PFC. There was a significant time ϫ group interaction [F(28,210) ϭ 10.14, P Ͻ 0.05, two-way ANOVA] and both METH and AMPH significantly raised NE levels [P Ͻ 0.05 compared to control at same time point, LSD test]. However, AMPH raised NE levels significantly more than METH did [P Ͻ 0.05 at 20-40, 40-60, and 60-80 min, LSD test].
Norepinephrine Release
Dopamine and Metabolite Release
DA levels from the control groups are shown in Fig. 2 . Normally, control injections of saline have no effect on DA levels [ Fig. 2] . However, during desipramine administration, DA levels became significantly elevated [ Fig. 2 (right); F(18,90) ϭ 3.21, P Ͻ 0.05, ANOVA; P Ͻ 0.05 at 0-20, 20-40, 40-60, 100-120, 140-160 min compared to baseline, LSD test] suggesting that desipramine by itself increased DA levels. Although desipramine altered DA levels, desipramine had no effect on DOPAC or HVA [data not shown].
The effects of desipramine treatment on METH and AMPH induced DA release are shown in Fig. 3 . Desipramine treatment significantly augmented the increase in DA levels induced by METH [ Fig. 3 (left); F(14,140) 
Serotonin Release
The 5-HT data are graphed in Fig. 5 . When given alone, neither AMPH nor METH increased 5-HT levels (data not shown). Saline normally did not affect 5-HT levels, but when desipramine was given, desipramine 
DISCUSSION
Amphetamine Induced NE and DA Release
As we have previously reported, AMPH has a greater effect on DA levels in the PFC than METH does, even though METH and AMPH have similar effects on DA levels in the NAC (2). In the PFC, where the NE to DA ratio is high, NETs are believed to play an important role in the removal of extracellular DA. In the NAC, where NE innervation is scarce, NETs are believed to have little or no effect on DA levels (9). Because we found AMPH to release more NE than METH does, the difference in DA release in the PFC between METH and AMPH could be due to differences in their effects on NETs.
Consistent with this hypothesis, administration of the NET blocker desipramine blocked the increase in DA induced by AMPH, a result similar to the effect of DAT blockers on AMPH-induced DA release in the NAC (12) . This suggests that AMPH may release DA in the PFC primarily through NETs. AMPH does have a higher affinity for the NET compared to the DAT (13), and because the NET does have a higher affinity for DA than for NE (6) , it is plausible that the NET is primarily responsible for the increase in extracellular PFC DA levels by AMPH. Indeed, it is believed that MDMA (methylenedioxymethamphetamine) releases DA via the NET in the hippocampus, another brain region with a high NE to DA ratio (14) . Because AMPH released more NE in the PFC than METH did, this could mean that AMPH interacts with the NE terminal to a greater extent than METH does, resulting in a greater release of both NE and DA from the NE terminal. Thus, when the NET is blocked with desipramine, AMPH is prevented from releasing DA from the NE terminal, and the amount of DA released by AMPH is significantly decreased. Because the NAC has low levels of NETs, the difference between METH and AMPH to interact with the NET would not be expected to lead to significant differences in efficacy to raise NAC DA levels, thereby explaining the observed differences between the PFC and the NAC.
Although the difference between METH and AMPH in raising NE levels was smaller than the difference between METH and AMPH in raising DA levels, this could reflect different mechanisms of action by METH and AMPH on NE and DA levels. Though NETs have been shown to reverse transport DA (15), NET does not appear to normally reverse transport NE (16, 17) . This may be because the NET has a higher affinity for DA than NE (6), and NE is synthesized and stored in vesicles (18) , so DA would be more likely than NE to bind to the inward facing NET for reverse transport. Therefore, if AMPH increases NE by primarily blocking uptake but DA by reverse transport, it would be expected that the small difference on NE levels between METH and AMPH would be magnified when observing DA levels. Alternatively, AMPH may act to release cytoplasmic dopamine and deplete vesicles, decreasing the amount of DA substrate available for NE synthesis, thus limiting the amount of NE that can be released.
Methamphetamine-Induced NE and DA Release
METH raised NE levels to a lesser degree than AMPH did, suggesting that METH interacts with the NET to a lesser degree than AMPH. Thus, under normal conditions, METH may have produced a smaller increase in DA levels compared to AMPH due to the smaller interaction with the NET. Consistent with this, METH does have a lower affinity for the NET than AMPH does (13) .
Because desipramine did not antagonize the METHinduced release of DA, it is possible that METH may instead release DA primarily from the DA terminal. However, under normal conditions, when NET is unblocked, this DA would be cleared away from the extracellular space by the NET. The result would be a small increase in extracellular DA levels by METH. When NET is blocked with desipramine, the DA released by METH from the DA terminal may be more apparent, as it is no longer removed by the NET. This suggests that METH is capable of releasing DA from the DA terminal to a greater extent than is AMPH; otherwise, when the NET was blocked with desipramine, AMPH would still release large amounts of DA from the DA terminal and a decrease in AMPH-induced DA release would not have been observed. Because AMPH and METH have similar effects on DA in the NAC, it is possible that the DAT is expressed differently or functions differently in the PFC than in the NAC (19, 20, 21) . Furthermore, in one study it was found that AMPH was not transported into the terminal by the DA transporter in the cortex as it was in the striatum (21) . The transport of AMPH into the terminal is a key step in the reverse transport of DA. Although, the ability of METH to be transported into the terminal by the DA transporter has not been examined, if METH, but not AMPH, were able to enter the PFC DA terminal, then this would explain the present results.
An alternative explanation for the increase in DA release by METH after desipramine treatment is that METH normally releases little DA and NE from the NE terminal, but the NE or 5-HT released by desipramine synergistically interacted with the glutamate (GLU) released by METH to cause an increase in DA release. The PFC projects to and controls the activity of DA neurons in the ventral tegmental area (22) . Both NE and 5-HT have been shown to excite PFC projection neurons, and this effect may rely on GLU (23, 24) . We have previously shown that METH, but not AMPH, stimulates GLU release in the PFC (2) . Therefore, the DA released by METH in the presence of desipramine may represent the synergistic combination of transporter-released DA by METH and impulse-dependent DA release through polysynaptic activation.
The Effect of Desipramine on Dopamine and Serotonin
Another interesting result was the effect of desipramine on DA and 5-HT release. Desipramine was found to raise extracellular DA levels, consistent with previous results (8) . However, this appears to be the first study to also examine the effects of desipramine on DOPAC and HVA. If desipramine raised DA levels only by blocking DA uptake through the NET, as previously assumed, then there should be an accompanying decrease in DOPAC and HVA. Also, the time course for the increase in DA was very slow, suggesting that this was instead an indirect effect of desipramine. The increase in 5-HT by desipramine was more immediate. There is substantial evidence indicating that 5-HT increases DA release in the PFC, by acting at presynaptic heteroreceptors (25) . Therefore, though DA uptake blockade may contribute to the increase in DA levels caused by desipramine, this effect may mostly be secondary to an increase in 5-HT.
The mechanism by which desipramine increased 5-HT levels remains unclear. The concentration of desipramine in the perfusate was 1 M, and the amount of desipramine delivered through the probe to the PFC by reverse dialysis would only be a small percentage (ϳ10%) of that. Because desipramine has a very low affinity for the 5-HT transporter (26) , this is most likely not a direct effect. Instead, the elevated NE produced by desipramine could act at presynaptic heteroreceptors to modify 5-HT release. However, the only documented presynaptic modulation of 5-HT by NE is a decrease in 5-HT release through ␣ 2 -adrenergic receptors (27) . Therefore, a multistep pathway or modulation of polysynaptic activity may be involved.
CONCLUSIONS
These results suggest that AMPH releases PFC DA primarily through NET, whereas METH interacts minimally with NET. These results indicate that METH and AMPH, two similar drugs, have very different pharmacological profiles in the PFC, an area important in the psychopathology of drug addiction. These profiles suggest that different treatments may be needed for METH and AMPH addictions.
